BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1353 related articles for article (PubMed ID: 17391494)

  • 21. Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study.
    Heldal D; Brinch L; Tjønnfjord G; Solheim BG; Egeland T; Albrechtsen D; Aamodt G; Evensen SA
    Bone Marrow Transplant; 2003 Aug; 32(3):257-64. PubMed ID: 12858196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
    Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
    Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A preliminary analysis of unrelated marrow transplantations facilitated by the Japan Marrow Donor Program (JMDP)].
    Okamoto S; Harada M; Kato S; Morishima Y; Imamura M; Tsuchiya S; Yamada Y; Kodo H; Hoshi Y; Tsuchida M
    Rinsho Ketsueki; 1995 Jun; 36(6):524-9. PubMed ID: 7643445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
    Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
    Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience.
    Bacigalupo A; Zikos P; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Mordini N; Bregante S; Berisso G; Vitale V; Sessarego M; Marmont AM
    Exp Hematol; 1998 May; 26(5):409-14. PubMed ID: 9590657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
    Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
    Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
    Tomás JF; Peñarrubia MJ; García JA; Figuera A; Gómez-García de Soria V; Steegmann JL; Arranz R; Cámara R; Gabriel R; Vázquez L
    Med Clin (Barc); 1995 Nov; 105(16):605-11. PubMed ID: 8523939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution.
    Nakai K; Mineishi S; Kami M; Saito T; Hori A; Kojima R; Imataki O; Hamaki T; Yoshihara S; Ohnishi M; Kim SW; Ando T; Fumitoh A; Kanda Y; Makimoto A; Tanosaki R; Kanai S; Heike Y; Ohnishi T; Kawano Y; Wakasugi H; Takaue Y
    Transplantation; 2003 Jun; 75(12):2135-43. PubMed ID: 12829926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.
    MacMillan ML; Radloff GA; Kiffmeyer WR; DeFor TE; Weisdorf DJ; Davies SM
    Transplantation; 2003 Dec; 76(12):1758-62. PubMed ID: 14688528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.
    Arnold R; de Witte T; van Biezen A; Hermans J; Jacobsen N; Runde V; Gratwohl A; Apperley JF
    Bone Marrow Transplant; 1998 Jun; 21(12):1213-6. PubMed ID: 9674854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor.
    Morishima Y; Yabe T; Matsuo K; Kashiwase K; Inoko H; Saji H; Yamamoto K; Maruya E; Akatsuka Y; Onizuka M; Sakamaki H; Sao H; Ogawa S; Kato S; Juji T; Sasazuki T; Kodera Y;
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):315-28. PubMed ID: 17317585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
    Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
    Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.